

**AMENDMENTS TO THE CLAIMS:**

Amend the claims as follows:

Claims 1-17. (Canceled)

18. (new) A method of treating multiple sclerosis (MS) comprising administering treosulphan and/or derivatives thereof to a person in need of such treatment, said method not comprising stem cell transplantation.

19. (new) A method of treating multiple sclerosis (MS) comprising administering treosulphan and/or derivatives thereof to a person in need of such treatment, said method being independent of stem cell transplantation.

20. (new) A method of treating multiple sclerosis (MS) comprising administering treosulphan and/or derivatives thereof to a person in need of such treatment, wherein administration of said treosulphan and/or derivatives thereof leads to an improvement of the ambulation index of said person.

21. (new) The method of claim 18, wherein said MS is a relapsing-remitting, primary progressive or secondary progressive MS.

22. (new) The method of claim 19, wherein said MS is a relapsing-remitting, primary progressive or secondary progressive MS.

23. (new) The method of claim 20, wherein said MS is a relapsing-remitting, primary progressive or secondary progressive MS.

24. (new) The method of claim 18, wherein said derivatives thereof are selected from the group consisting of busulphan, dimethyl busulphan, pentasulphan or hepsulphan.

25. (new) The method of claim 19, wherein said derivatives thereof are selected from the group consisting of busulphan, dimethyl busulphan, pentasulphan or hepsulphan.

26. (new) The method of claim 20, wherein said derivatives thereof are selected from the group consisting of busulphan, dimethyl busulphan, pentasulphan or hepsulphan.

27. (new) The method of claim 18, wherein said treosulphan or derivatives thereof are administered in the amount of 1 to 10 grams of treosulphan and/or treosulphan derivative per m<sup>2</sup> of body surface.

28. (new) The method of claim 19, wherein said treosulphan or derivatives thereof are administered in the amount of 1 to 10 grams of treosulphan and/or treosulphan derivative per m<sup>2</sup> of body surface.

29. (new) The method of claim 20, wherein said treosulphan or derivatives thereof are administered in the amount of 1 to 10 grams of treosulphan and/or treosulphan derivative per m<sup>2</sup> of body surface.

30. (new) The method of claim 27, wherein said treosulphan or derivatives thereof are administered in the amount of 3 to 9 grams per m<sup>2</sup> of body surface.

31. (new) The method of claim 28, wherein said treosulphan or derivatives thereof are administered in the amount of 3 to 9 grams per m<sup>2</sup> of body surface.

32. (new) The method of claim 29, wherein said treosulphan or derivatives thereof are administered in the amount of 3 to 9 grams per m<sup>2</sup> of body surface.

33. (new) The method of claim 27, wherein said treosulphan or derivatives thereof are administered in the amount of 5 to 8 grams per m<sup>2</sup> of body surface.

34. (new) The method of claim 28, wherein said treosulphan or derivatives thereof are administered in the amount of 5 to 8 grams per m<sup>2</sup> of body surface.

35. (new) The method of claim 29, wherein said treosulphan or derivatives thereof are administered in the amount of 5 to 8 grams per m<sup>2</sup> of body surface.

36. (new) The method of claim 18, wherein said method further comprises administration of at least one amino immunomodulatory effective substance.

37. (new) The method of claim 19, wherein said method further comprises administration of at least one amino immunomodulatory effective substance.

38. (new) The method of claim 20, wherein said method further comprises administration of at least one amino immunomodulatory effective substance.

39. (new) The method of claim 36, wherein said immunomodulatory effective substance is interferon- and/or glatiramer acetate.

40. (new) The method of claim 37, wherein said immunomodulatory effective substance is interferon- and/or glatiramer acetate.

41. (new) The method of claim 38, wherein said immunomodulatory effective substance is interferon- and/or glatiramer acetate.

42. (new) The method according to claim 18, wherein said administering comprises administration of infusion solution or an oral formulation.

43. (new) The method according to claim 19, wherein said administering comprises administration of infusion solution or an oral formulation.

44. (new) The method according to claim 20, wherein said administering comprises administration of infusion solution or an oral formulation.